Request paper copies of the above proxy materials online now, by email
or by phone by dialing
866-648-8133.
June 26, 2026
4:00 p.m. Eastern Time
We are Inhibikase Therapeutics, a pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of pulmonary arterial hypertension (PAH).